LABORATORY RESEARCH Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer Scientists found that MYB is transcriptionally activated by androgen deprivation therapy or genetic silencing of the androgen receptor. MYB silencing inhibited prostate cancer growth in culture and xenografts in mice. [Sci Signal] Abstract Evaluating the Anticancer Properties of Liposomal Copper in a Nude Xenograft Mouse Model of Human Prostate Cancer: Formulation, In Vitro, In Vivo, Histology and Tissue Distribution Studies A stealth liposomal Cu formulation (LpCu) was studied in vitro and in vivo. LpCu was evaluated in prostate cancer origin PC-3 cells by a metabolic cytotoxicity assay, by monitoring ROS, and by flow cytometry. [Pharm Res] Abstract Antitumor Effects of Oncolytic Adenovirus Armed with PSA-IZ-CD40L Fusion Gene against Prostate Cancer Scientists developed a prostate cancer-specific oncolytic adenovirus armed with fusion gene of prostate-specific antigen and CD40 ligand, and evaluated its therapeutic effect in vitro and in vivo. [Gene Ther] Abstract Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer Scientists report hsa-miR-765 as the first fulvestrant-driven, estrogen receptor β-regulated miRNA exhibiting significant tumor suppressor activities like fulvestrant, against prostate cancer cell growth via blockage of cell-cycle progression at the G2/M transition, and cell migration and invasion possibly via reduction of filopodia/intense stress-fiber formation. [PLoS One] Full Article | Press Release Rac1-Dependent Lamellipodial Motility in Prostate Cancer PC-3 Cells Revealed by Optogenetic Control of Rac1 Activity Researchers revealed the role of phosphatidylinositol 3-kinase in Rac1-dependent lamellipodial motility in PC-3 prostate cancer cells. [PLoS One] Full Article Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS In Vitro and In Vivo Researchers investigated the effects of metformin, a widely used antidiabetic drug, on tumor cell radiosensitivity in prostate cancer. Through clonogenic survival assays, they found that metformin treatment enhanced radiosensitivity of prostate cancer cells with a dose enhancement factor. [Radiat Res] Abstract Chrebp Regulates the Transcriptional Activity of Androgen Receptor in Prostate Cancer By way of immunoprecipitation followed by mass spectrometry system, researchers found that carbohydrate-responsive element-binding protein (Chrebp), a glucose sensor in normal and cancer cells, interacted with androgen receptor in LNCaP cells. [Tumor Biol] Abstract Restoration of Fibroblast Growth Factor Receptor 2IIIb Enhances the Chemosensitivity of Human Prostate Cancer Cells Researchers determined whether fibroblast growth factor receptor 2 (FGFR2)IIIb plays a role in the chemosensitivity of castration-resistant prostate cancer cells. The effects of chemotherapeutic agents on cell viability and apoptosis were examined by MTT assay and western blot analysis, respectively. [Oncol Rep] Abstract CLINICAL RESEARCH Randomized Phase II Study of Nintedanib in Metastatic Castration-Resistant Prostate Cancer Postdocetaxel This open-label, Phase II trial assessed the efficacy and safety of two doses of nintedanib, a triple angiokinase inhibitor targeting vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor signaling, in patients with metastatic castration-resistant prostate cancer following progression on docetaxel-based regimens. [Anticancer Drugs] Abstract Diagnostic Ability of %p2PSA and Prostate Health Index for Aggressive Prostate Cancer: A Meta-Analysis Scientists conducted a meta-analysis to evaluate the diagnostic performance of [-2]proPSA/free PSA (%p2PSA) and prostate health index tests for prostate cancer and to evaluate their ability in discriminating between aggressive and non-aggressive prostate cancer. [Sci Rep] Full Article |